Compugen Ltd. (NASDAQ:CGEN) reached a new 52-week low on Thursday . The stock traded as low as $3.10 and last traded at $3.15, with a volume of 69,191 shares trading hands. The stock had previously closed at $3.35.

Several equities research analysts have recently weighed in on CGEN shares. FBR & Co set a $14.00 price objective on Compugen and gave the company a “buy” rating in a report on Friday, May 19th. Zacks Investment Research downgraded Compugen from a “hold” rating to a “sell” rating in a report on Monday, May 22nd.

The stock’s market capitalization is $158.51 million. The firm’s 50 day moving average is $3.75 and its 200-day moving average is $4.20.

Compugen (NASDAQ:CGEN) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.17) by $0.01. Compugen had a negative net margin of 4,425.00% and a negative return on equity of 57.69%. On average, analysts predict that Compugen Ltd. will post ($0.73) EPS for the current fiscal year.

Several large investors have recently modified their holdings of CGEN. Renaissance Technologies LLC increased its stake in shares of Compugen by 15.6% in the fourth quarter. Renaissance Technologies LLC now owns 534,900 shares of the biotechnology company’s stock worth $2,728,000 after buying an additional 72,075 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Compugen by 522.2% in the first quarter. Tower Research Capital LLC TRC now owns 23,576 shares of the biotechnology company’s stock worth $101,000 after buying an additional 19,787 shares during the period. Norges Bank purchased a new stake in shares of Compugen during the fourth quarter worth $658,000. Raging Capital Management LLC increased its stake in shares of Compugen by 35.3% in the first quarter. Raging Capital Management LLC now owns 4,236,522 shares of the biotechnology company’s stock worth $18,217,000 after buying an additional 1,104,391 shares during the period. Finally, Vident Investment Advisory LLC increased its stake in shares of Compugen by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 150,614 shares of the biotechnology company’s stock worth $648,000 after buying an additional 25,100 shares during the period. Institutional investors and hedge funds own 19.37% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/10/compugen-ltd-nasdaqcgen-sets-new-1-year-low-at-3-10.html.

About Compugen

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.

Receive News & Stock Ratings for Compugen Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen Ltd. and related stocks with our FREE daily email newsletter.